Comparison of six activated partial thromboplastin time reagents: intrinsic system factors' sensitivity and responsiveness. 1990

S C Hales, and G S Johnson, and D Wagner
Specialized Coagulation Laboratory, Humana Hospital Audubon, Louisville, KY 40217.

Six activated partial thromboplastin reagents from four manufacturers were evaluated for precision, sensitivity, and dose responsiveness to Factors VIII, IX, and XII. Normal and abnormal APTT samples were prepared. Precision was assessed using 10 replicates on three consecutive days. Factor sensitivity and responsiveness were measured using a log-log curve of percent activity versus the upper limit of normal of prepared samples. All reagents had acceptable precision (C.V. less than 5%) in the normal range, but three performed unacceptably in the abnormal range. Two of the reagents were determined to be too sensitive to certain factors, giving an abnormal APTT result when the factor activity was in the normal range. Sensitivity and dose responsiveness to factors should be considered as two separate characteristics of an APTT reagent.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D011933 Reagent Kits, Diagnostic Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use. Diagnostic Reagent Kits,Diagnostic Reagents and Test Kits,Diagnostic Test Kits,In Vitro Diagnostic Device,In Vitro Diagnostic Devices,In Vitro Diagnostic Medical Device,In Vitro Diagnostic Medical Devices,Kits, Diagnostic Reagent,Diagnostic Reagent Kit,Diagnostic Test Kit,Kit, Diagnostic Reagent,Kit, Diagnostic Test,Kits, Diagnostic Test,Reagent Kit, Diagnostic,Test Kit, Diagnostic,Test Kits, Diagnostic
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005164 Factor IX Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease). Autoprothrombin II,Christmas Factor,Coagulation Factor IX,Plasma Thromboplastin Component,Blood Coagulation Factor IX,Factor 9,Factor IX Complex,Factor IX Fraction,Factor Nine,Factor IX, Coagulation
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D005174 Factor XII Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III. Coagulation Factor XII,Hageman Factor,Factor 12,Factor Twelve
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S C Hales, and G S Johnson, and D Wagner
April 1973, American journal of clinical pathology,
S C Hales, and G S Johnson, and D Wagner
June 1978, Thrombosis and haemostasis,
S C Hales, and G S Johnson, and D Wagner
June 1993, British journal of biomedical science,
S C Hales, and G S Johnson, and D Wagner
January 1986, American journal of clinical pathology,
S C Hales, and G S Johnson, and D Wagner
May 1974, American journal of clinical pathology,
S C Hales, and G S Johnson, and D Wagner
March 1974, American journal of clinical pathology,
S C Hales, and G S Johnson, and D Wagner
February 1976, American journal of clinical pathology,
S C Hales, and G S Johnson, and D Wagner
August 2016, International journal of laboratory hematology,
S C Hales, and G S Johnson, and D Wagner
December 1994, British journal of biomedical science,
Copied contents to your clipboard!